Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health.

Slides:

Advertisements

Similar presentations

Marta José, Instituto Grifols S.A., Barcelona, SPAIN

Advertisements

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.

National Institute for Biological Standards and Control Assuring the quality of biological medicines Proposal for a Hepatitis A genotype panel Rob Anderson.

Proposal to Prepare Reference Panels & Standards for Hepatitis E Virus

State of Hepatitis C in Ghana

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Use of avidity reagent. Panbio Buffered Avidity Reagent Mild protein-denaturing solution that may be useful in differentiating recent infections from.

Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.

Update on West Nile virus and Blood Safety November 3, 2005 Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

HEV in Belgium: An import infection or an emerging viral zoonosis? I.Micalessi, I.Thomas, B. Brochier National Center of Viral Hepatitis Rue Juliette Wytsmanstraat.

Evaluation of Cloned DNA for B19 Genotypes Dr Jacqueline Fryer, Division of Virology NIBSC.

F. Kourgia, M. Vini, E. Zervou

HIV Testing CDC power point edited by M. Myers

Full characterization of HAV RNA window period positive blood donations in Germany SoGAT XVIII Bethesda.

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?

Detection of parvovirus B19 and novel human parvoviruses in high-risk individuals Ashleigh Manning 1, Kate Templeton 2, Ed. Gomperts 3, Peter Simmonds.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.

Lara Isobel Compston, Daniel Candotti, Jean-Pierre Allain

Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.

DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.

Level of viraemia and genotype characteristics of Parvo B19 in blood donors and patients Brojer E, Grabarczyk P Depatment of Immuhematology Institute of.

Update on Assay Development George J. Dawson, Ph.D. Infectious Diseases: Core R & D Abbott Laboratories West Nile Virus.

Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.

Commercial Assays and Detection of Parvovirus B19 genotypes Dr Sally A. Baylis, Division of Virology NIBSC.

Parvovirus B19 Genotype 2 Plasma, Sourced from the US Dr Sally A. Baylis, Division of Virology NIBSC.

An Update on FDA/OBRR XMRV activities BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of Molecular Virology DETTD/CBER/FDA.

NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.

Phylogenetic analysis of genotype 3 parvovirus B19 in Ghana, West Africa.

Active B19 virions production in hepatoblastoma and hepatocarcinoma cell lines: amplification and genomic stability. Op de beeck A. 1, Draps M.-L. 1, Baurin.

1 Summary September 25-26, 2006 FDA Workshop Molecular Methods in Immunohematology 89 th Meeting of BPAC April 27, 2007 Sheryl A. Kochman Chief, Devices.

Anti-B19 screening for safe cellular blood products for at–risk patients SoGAT XVIII, USA, May 24-25th, 2005 Harry Bos on behalf of Project Group Parvo.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

Our tryst with Nucleic Acid Testing Dolly Daniel, Dept of Transfusion Medicine, CMC, Vellore.

Natural history of HBV infection (adapted from Torbenson Lancet 2003) Chronic infection Healthy carriage Recovery occult DNA Anti-HBe Anti-HBc Immune response.

SoGAT 2005 Donor screening for parvovirus B19 antibodies: Reducing or eliminating the risk of transmission SoGAT 2005 Gordon Elliott Biotrin 93 The Rise.

Maternofetal transmission of human parvovirus B19 genotype 3 in Ghana, West Africa D Candotti, K Danso, A Parsyan, A Dompreh, J- P Allain National Blood.

Human Parvoviruses Kevin E Brown Immunisation and Diagnosis Unit Virus Reference Department Centre for Infections.

Genotype analysis of anti-B19 IgM positive sera from Brazil Kevin E Brown Immunisation and Diagnosis Unit Virus Reference Department Centre for Infections.

Novel and Related Variant Parvoviruses in Human Plasma Jacqueline Fryer and Sally Baylis National Institute for Biological Standards and Control Eric Delwart.

Holland Laboratory David A. Leiby, PhD Transmissible Diseases Department American Red Cross Holland Laboratory and Department of Microbiology and Tropical.

HBV genotypes E and A deletions and recombination: two sides of the same coin? Penelope Garmiri 1, Andre Loua 2, Daniel Candotti 3 and Jean-Pierre Allain.

RESULTS Division of Arboviruses, Center for Immunology and Pathology, National Institute of Health, Korea Centers for disease control, Osong, Korea BACKGROUND.

Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.

SOGAT Presence (absence) of genotype 2 and 3 Erythrovirus DNA in manufacturing plasma Theo Cuypers, Marco Koppelman, Margret Sjerps, Henk Reesink.

Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.

Abbott Laboratories ConfidentialPage 1 Update on West Nile Virus George J. Dawson, Ph.D. Abbott Laboratories.

 Cytomegalovirus (CMV) is the commonest among viral infections during perinatal period that cause congenital infections  Seroprevalence in pregnant.

LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA

Experience in Testing of Genotypes of B19

Prevalence of oncogenic Human Papillomavirus genotypes in women with vulvar and cervical squamous cell carcinoma in Botswana Patricia Rantshabeng1,2 ,

Human Parvovirus PARV4 in Blood and Plasma Products

GRIFOLS PLASMA: genotype 2 vB19 sample

Testing for Parvovirus B19 - Broadening the Assay to Cover Variants

Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology

FACILITATOR VERSION Case Four: I just have antibodies to this

Volume 384, Issue 9956, Pages (November 2014)

Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K

NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:

Distributions of parvovirus B19 genotype 1-3 in blood donations

SERO-CHARACTERIZATION OF HUMAN CYTOMEGALOVIRUS AMONG PREGNANT WOMEN IN THIKA. PUBLISHERS: Zakayo Maingi (corresponding author) Dr Anthony Kebira Prof.

Comparison of a commercial and ‘in house’ assay for B19 DNA

SoGAT meeting XXI May (2009), Brussels, Belgium

FACILITATOR VERSION Case Four: I just have antibodies to this

Presentation transcript:

Persistent human erythrovirus infection in blood donors National Blood Service, UK Div. Transfusion Medicine, University of Cambridge, UK Public Health Laboratory, Ankara, Turkey D Candotti, N Etiz, A Parsyan, JP Allain

Issues and objectives Background Chronic anaemia may occur in transfused immunosuppressed patients Some preliminary evidence of persistent B19 infection (DNA+IgG) Study objectives - to determine the prevalence of persistent B19 infection in blood donors - to characterise persistent B19 genome - to assess the potential infectivity of persistent B19

NAT assays Human erythrovirus genotypes (HEV 1 (NIBSC 99/800) 2 (EDQM) 3 (D91.1 plasmid) Nested-PCR 1 95% detection limit 2 Q-PCR 3 95% detection limit 2 Dynamic range x x x Primers in the NS1 region 2. IU/ml or copies/ml 3. TaqMan-based assay using primers and probe in the NS1 region

Human erythrovirus DNA in blood donors

UK South Africa Malawi References Genotype 1 Genotype 2 Genotype 3 Ghana Phylogenetic analysis of human erythrovirus 800 nt NS1/VP1u sequences

Serology of HEV DNA+ samples (Biotrin IgM & IgG kits) UK Ghana Pos Neg Pos Neg IgM IgG * 2 * S/COs of positives are significantly lower than with UK samples

Sample id: IgG status: UK4523 positive UK4892 positive Gh2094 positive Gh2120 positive Gh1280 negative Gh2135 negative % of the viral population Eluted Flow through HEV DNA quantification in 6 plasmas chromatographed on protein G

IgG antibody to HEV genotype 1 and 3 CountryN samples Reactive to antigen (%) testedGenotype 1Genotype 3* UK (60.9) ND Ghana (70.3) 117 (75.5) * VP2 antigen from V9 strain was provided by Dr K Brown, NIH, USA

Conclusions The prevalence of persistent human erythrovirus infection in random blood donors is approximately 1% Viral load in persistent HEV infections is low (median 10E3) 5-70% of persistent HEV appears uncomplexed (free) HEV Genotype 3 is prevalent in Ghana Serologic detection of antibody to genotype 3 with genotype 1 reagent is unsatisfactory

Acknowledgements Transfusion Medicine Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana Francis Sarkodie Shirley Owusu-Ofore National Institute for Biological Standards and Control, UK Dr. Sally Baylis Liverpool School of Tropical Medicine, UK Dr. Imelda Bates Natal Blood Transfusion Service, Pinetown, South Africa Dr. Theresa Nel Virology Lab., Armand trousseau Hospital, Paris, France Dr. Annabelle Servant Pr. Antoine Garbarg-Chenon Dept. of Microbiology, Scientific Institut of Public Health, Brussels, Belgium Dr. Isabelle Thomas Hematology branch, National Heart, Lung, and Blood Institut, Bethesda, USA Dr. Kevin Brown West Khartoum Umdurman Hospital Khartoum, Sudan Dr. A Youssef